Prostrakan Share Discussion Threads

[password] 12/7/2007 12:14

Morgan Stanley's recommendations are not that surprising, afterall they are the Prostrakan's Financial Advisors and Brokers. Market at the moment certainly doesnt seem to agree with them!

[pip] 09/7/2007 10:47

Well the share price hasn't moved much but there was also a very positive piece under Share Tips in the Business Section of the Sunday Telegraph. It ends with Morgan Stanley's price target of 153p and a buy recommendation.

[bogg1e] 09/7/2007 09:41

The Independant over the weekend tipped psk as a buy with target price of 133p.

[ariane] 06/7/2007 07:36

Fri 6 Jul 2007

ProStrakan's new sales team targets Italy
HAMISH RUTHERFORD
PROSTRAKAN, the Borders pharmaceutical company, was boosted after revealing better than expected sales and a new partner to give it a sales force in all major European markets.

Sales grew by 15 per cent in the six months to 30 June, slightly ahead of analyst expectations, boosted by sales of newly launched pan-European drugs Rectogesic, a treatment for anal fissures, and Tostran, a testosterone replacement therapy for ageing men.

Chief executive Wilson Totten said sales had been slightly better than expected, with the sales force responding well and Tostran, targeted as a treatment for loss of libido and erectile dysfunction, attracting large levels of media coverage.

Shares rose 4.7 per cent to 83.5p, up from an all-time low of 79p earlier this week, to value the company at £168 million.

ProStrakan has also established a sales force in Italy through Keryos Spa. The sales force of 140 is the most of any of ProStrakan's markets, and give it access to all major European countries.

While currently Europe is the main focus, in the medium term ProStrakan expects to move focus to the US, where it has made its first fillings with the FDA over clinical trials. Totten said the company planned to have a sales force in place in the US by the second half of 2008, potentially by buying an existing company. However, although the company could then control its own US programme, he said it was "more likely" that the company's first step into the region would not be an acquisition "although that could follow shortly after".

An update on the probable make up of the US operation is expected when the company reports its interim results on 12 September .

Related topic

ProStrakan

This article:

Last updated: 05-Jul-07 00:08 BST

[ariane] 05/7/2007 07:35

ProStrakan reports 'strong' H1 performance; product sales up 15 pct


LONDON (Thomson Financial) - Small-cap specialty pharmaceutical company
ProStrakan Group PLC said it "performed strongly" in the first half of the year,
with revenues from product sales growing 15 pct.
In a trading statement the company said recently launched pan-European
products Tostran, Rectogesic and Droperidol generated sales growth of 43 pct.
Total revenues, which includes milestone payments, climbed 28 pct.
ProStrakan said the increasing proportion of revenues emanating from newer
products, together with its growing portfolio of global rights, contributed to
an expected improvement in gross margins.
The group also revealed that its anti-sickness patch Sancuso was filed with
the US Food and Drug Administration on June 29, adding that a submission with
European regulators will be made "in coming weeks".
Additionally, ProStrakan announced a new distribution agreement with
privately held Italian pharmaceutical company Keryos.
[e-mail]
ab

[ricartonl] 04/7/2007 11:18

i couldn't

the overdraft facility seems to have had an impact on the share price since it was announced. im sure the interest accrued won't help the balance sheet.

hopefully the company can shed some positive light, soon.

//added
they stated 2007 progress will be detailed in an RNS tomorrow

[password] 29/6/2007 16:39

Looks like you might get your chance, puzzled by why the slide? can you throw any light on the reason for decline

[ricartonl] 29/6/2007 14:09

ah yes, the MMs must have took note, eh.

im waiting for 75p

[password] 28/6/2007 10:38

Has it? see todays figures

[ricartonl] 27/6/2007 17:50

any "chartists"?

looks like it's broken the downtrend.

[password] 15/6/2007 16:52

MARIETTA, Ga., June 14, 2007 /PRNewswire/ -- Solvay Pharmaceuticals, Inc., announced today that it submitted a supplemental New Drug Application (sNDA) for AndroGel(R) (testosterone gel) 1% CIII to the U.S. Food and Drug Administration (FDA) for treatment in male adolescents ages 13-17 years old with primary or secondary hypogonadism. Solvay Pharmaceuticals also is seeking an additional indication for AndroGel in the treatment of Constitutional Delay in Growth and Puberty (CDGP) in male adolescents.

Solvay Pharmaceuticals proposes to market the product under the trade name AndroGel PD for these two indications. As part of the application for new indications, the company has requested a review of the application for Pediatric Exclusivity designation. If granted, this would extend patent protection for AndroGel by six months.

While hypogonadism is commonly associated with men ages 45 and older, it can occur in males of any age, including teens between the ages of 13-17 years old. More than 32,000 males between the ages of 13 and 17 may require testosterone therapy to initiate puberty. Combined with Klinefelter's syndrome alone, the potential population exceeds 50,000 adolescent males.

[password] 15/6/2007 16:24

What is going on with this one? new product launch with good media coverage yet share price seems to be finding new bottoms faster than their Retrogesic brand

[ricartonl] 15/6/2007 14:47

RNS Number:4612Y
ProStrakan Group plc
15 June 2007

15 June 2007


ProStrakan Group plc

2007 Financial Calendar Update


Pre-Close Statement

Six months ending 30 June 2007


ProStrakan Group plc will issue a pre-close statement on Thursday, 5th July
2007. This will be followed by an analyst conference call at 09:00hrs (BST).
Dial in details will be distributed in due course.


Interim Results

Six months ending 30 June 2007


ProStrakan Group plc will announce its interim results for the six months ending
30 June 2007 on Wednesday 12 September. Management will host a presentation in
London on the same day.


Year ending 31 December 2007

Pre-Close Statement


ProStrakan Group plc will issue a pre-close statement before entering its close
period in January 2008 (date to be confirmed in due course).


Enquiries:


Mo Noonan

FD

[phone]

[cjaj2] 12/6/2007 13:28

BBC covered the launch of the testosterone gel...


Lets hope it has good sales.

[password] 11/6/2007 11:23

Interesting, but not sure of signifance as already 6 or 8 brands with various formulations of Testosterone already on UK market - patch, tablet injection, and gel, one of which only needs to be taken every 3 months by injection. Maybe dose accuracy is the "thing"

[password] 30/5/2007 16:19

quiet! an understatement, a bit like the information flow. Will have to come below 70/75 for the risk and likely lengthy wait to be worthwhile.

[trojan] 30/5/2007 15:53

password..

From the small amount of info/research I have done so far the company seems to have the right management to build a big organisation here methinks but it's still early day's.

The question is as always wether to get in now and hold or trade elsewhere and then jump in on the back of any good news etc.

I will keep looking in but it is a very quiet thread. ;)

[password] 30/5/2007 15:14

yes if the product portfolio was looking better but with growing healtheconomic issues in healthcare.....

[trojan] 30/5/2007 14:14

Still on my monitor and keeping a close eye on this one.

If it dips under 80p to buy on no news it may well be worth a buy imo but i'll wait and see!!

[password] 30/5/2007 13:48

Glad I didnt follow your suggestion (philipsaxon) seems to be going further down and no news to speak of from Company

[maiseymouse] 24/4/2007 07:04

The credit Suisse downgrade is a bit severe but i'm not sure i understand the rationale for the change. does a change in valuation methodology effectively mean the broker got its sums wrong? I reckon, but then I'm not paid hundreds of thousands of pounds a year to analyse these things.